Cytori Therapeutics Inc (NASDAQ:CYTX) shares rose 7.7% on Wednesday . The stock traded as high as $0.30 and last traded at $0.28. Approximately 758,792 shares were traded during trading, an increase of 28% from the average daily volume of 593,002 shares. The stock had previously closed at $0.26.
CYTX has been the topic of several recent analyst reports. ValuEngine lowered shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Maxim Group reissued a “hold” rating on shares of Cytori Therapeutics in a research note on Monday, April 1st.
The company has a market capitalization of $4.72 million, a price-to-earnings ratio of -0.17 and a beta of 2.13. The company has a current ratio of 0.46, a quick ratio of 0.30 and a debt-to-equity ratio of 0.39.
Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. The business had revenue of $0.70 million for the quarter.
A number of institutional investors and hedge funds have recently made changes to their positions in CYTX. Barclays PLC lifted its stake in Cytori Therapeutics by 724.4% in the fourth quarter. Barclays PLC now owns 99,747 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 87,647 shares in the last quarter. Virtu Financial LLC lifted its stake in Cytori Therapeutics by 236.8% in the first quarter. Virtu Financial LLC now owns 141,209 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 99,279 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Cytori Therapeutics by 81.9% in the first quarter. Renaissance Technologies LLC now owns 338,712 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 152,464 shares in the last quarter. 4.08% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Cytori Therapeutics (CYTX) Stock Price Up 7.7%” was published by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2019/05/24/cytori-therapeutics-cytx-stock-price-up-7-7.html.
About Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.
Recommended Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.